KLIK-51MQ 100mg

KLIK-51MQ 100mg is based on research surrounding MOTS-c, a naturally occurring mitochondrial-derived peptide (MDP) that has attracted significant scientific interest for its potential role in regulating cellular energy metabolism. Unlike most signalling peptides encoded within the nuclear genome, MOTS-c is encoded by mitochondrial DNA, making it one of the first recognised examples of mitochondria functioning as endocrine signalling organelles. Since its discovery in 2015, MOTS-c has been investigated for its potential influence on metabolic flexibility, glucose utilisation, mitochondrial adaptation, skeletal muscle physiology and healthy ageing. Research suggests that MOTS-c may function as a stress-responsive signalling molecule, helping cells adapt to periods of metabolic challenge such as fasting, exercise, caloric restriction or oxidative stress. Although laboratory and animal studies have generated considerable interest, human research remains in its early stages. Many proposed physiological effects have yet to be confirmed in large, well-controlled clinical trials. Consequently, MOTS-c remains an investigational peptide within the broader field of mitochondrial biology.

SCIENTIFIC BACKGROUND For many years, mitochondria were viewed primarily as the cell's energy-producing structures, responsible for generating adenosine triphosphate (ATP) through oxidative phosphorylation. More recent research has expanded this understanding considerably. Mitochondria are now recognised as active signalling organelles involved in regulating cellular metabolism, oxidative stress responses, inflammation, programmed cell death (apoptosis), exercise adaptation, ageing and communication between tissues. The discovery of mitochondrial-derived peptides — including MOTS-c, Humanin and SHLP peptides — has introduced a new area of research exploring how mitochondria communicate with the rest of the body. MOLECULAR BIOLOGY MOTS-c is encoded within the 12S ribosomal RNA region of mitochondrial DNA, distinguishing it from conventional peptide hormones encoded by nuclear genes. The peptide consists of sixteen amino acids and appears capable of relocating from mitochondria to the nucleus under conditions of metabolic stress. Researchers have proposed that this translocation enables MOTS-c to influence expression of genes involved in cellular adaptation and energy metabolism. Although the exact molecular mechanisms continue to be investigated, this signalling pathway represents one of the most distinctive aspects of MOTS-c biology.

PROPOSED MECHANISMS Current evidence suggests that MOTS-c influences several interconnected metabolic pathways rather than acting through a single receptor. Areas under investigation include AMPK activation, glucose metabolism, fatty acid oxidation, mitochondrial function, oxidative stress, exercise adaptation and nuclear gene regulation. Many of these mechanisms remain incompletely characterised. AMPK ACTIVATION One of the best-studied proposed mechanisms involves activation of AMP-activated protein kinase (AMPK). AMPK functions as a cellular energy sensor. When energy availability decreases, AMPK coordinates adaptive responses including increased glucose uptake, enhanced fatty acid oxidation, reduced lipid synthesis, improved mitochondrial efficiency and increased energy production. Several experimental studies suggest MOTS-c may indirectly stimulate AMPK signalling, although the precise upstream mechanisms remain under investigation. GLUCOSE METABOLISM Animal studies indicate MOTS-c may improve several aspects of glucose regulation. Investigated effects include increased skeletal muscle glucose uptake, improved insulin sensitivity, reduced hepatic glucose production and enhanced metabolic flexibility. Most evidence currently originates from rodent models; only limited human data are available. MITOCHONDRIAL ADAPTATION Exercise and metabolic stress stimulate mitochondrial adaptation through coordinated signalling pathways. Researchers have proposed that MOTS-c contributes to these adaptive responses by influencing mitochondrial biogenesis, cellular stress resistance, ATP production, reactive oxygen species signalling and cellular resilience. Further work is required to clarify whether these findings translate into meaningful physiological adaptations in humans.

EXERCISE PHYSIOLOGY Exercise represents one of the most active areas of MOTS-c investigation. Animal studies have examined effects on running endurance, skeletal muscle adaptation, exercise capacity, fat oxidation and recovery following metabolic stress. Several experiments reported improvements in physical performance in aged mice following MOTS-c administration. Researchers have suggested that mitochondrial signalling peptides may contribute to some of the systemic health benefits associated with regular physical activity. Human confirmation remains limited. AGEING RESEARCH Ageing is associated with progressive changes in mitochondrial function. Scientific investigations have explored whether mitochondrial-derived peptides contribute to healthy ageing by influencing cellular stress resistance, metabolic regulation, muscle function, inflammation and insulin sensitivity. Some observational studies suggest circulating MOTS-c concentrations may change with age. Whether these changes contribute to ageing or simply reflect broader metabolic alterations remains unknown. HUMAN CLINICAL EVIDENCE Human research involving MOTS-c remains limited. Published investigations have primarily focused on circulating MOTS-c concentrations, exercise physiology, metabolic biomarkers and age-related changes. At present, there are no large randomised clinical trials demonstrating long-term clinical outcomes. Most mechanistic understanding continues to derive from laboratory research. Future clinical investigations are expected to expand understanding of its physiological significance. EVIDENCE STRENGTH • Animal metabolic studies — strong • Exercise physiology (animals) — strong • Cellular mechanism research — strong • Human biomarker studies — limited • Large human clinical trials — very limited

The pharmacokinetic profile of exogenous MOTS-c remains incompletely characterised. Areas requiring further investigation include: • Absorption • Distribution • Tissue targeting • Metabolism • Elimination • Biological half-life Unlike many approved peptide therapeutics, comprehensive pharmacokinetic data are not yet available.

SAFETY PROFILE Published human safety information remains limited. Animal investigations have generally reported acceptable tolerability within experimental settings. However, important questions remain regarding long-term administration, immunogenicity, off-target effects, repeated exposure and clinical safety. Large-scale human safety studies have not yet been completed. RESEARCH LIMITATIONS Current understanding of MOTS-c is limited by several factors: • Small number of human studies • Predominantly animal-based evidence • Limited pharmacokinetic data • Incomplete understanding of receptor biology • Short follow-up periods • Absence of large clinical outcome trials Current evidence should be interpreted as preliminary.

Scientific interest continues to expand in several areas. Current priorities include: • Healthy ageing • Sarcopenia • Exercise adaptation • Insulin resistance • Obesity • Type 2 diabetes • Mitochondrial diseases • Precision metabolic medicine Advances in mitochondrial biology are expected to improve understanding of how mitochondrial-derived peptides regulate whole-body physiology.